PARP1 and neoplasm: By blocking this FL-AR-induced ‘BRCAness’ gene set with enzalutamide in the LNCaP and VCaP cell lines, cells were sensitized to the PARP inhibitor olaparib; providing evidence of a novel combined treatment strategy involving anti-androgens and PARP blockade to potentiate enhanced tumour cell killing.